Search by Drug Name or NDC
NDC 59676-0575-30 PREZCOBIX 150; 800 mg/1; mg/1 Details
PREZCOBIX 150; 800 mg/1; mg/1
PREZCOBIX is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Janssen Products LP. The primary component is COBICISTAT; DARUNAVIR ETHANOLATE.
MedlinePlus Drug Summary
The combination of darunavir and cobicistat is used, along with other medications, to treat human immunodeficiency virus (HIV) infection in adults and children who weigh at least 88 lb (40 kg). Darunavir is in a class of medications called protease inhibitors. It works by decreasing the amount of HIV in the blood. Cobicistat is in a class of medications called pharmacokinetic boosters. It works by increasing the amount of darunavir in the body so that it can have a greater effect. Although darunavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting the HIV virus to other people.
Related Packages: 59676-0575-30Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Darunavir and Cobicistat
Product Information
| NDC | 59676-0575 |
|---|---|
| Product ID | 59676-575_02fc8dd6-7aed-29fb-e063-6394a90acf70 |
| Associated GPIs | 12109902270320 |
| GCN Sequence Number | 073052 |
| GCN Sequence Number Description | darunavir/cobicistat TABLET 800-150 MG ORAL |
| HIC3 | W5P |
| HIC3 Description | ANTIVIRALS, HIV-SPEC, NON-PEPTIDIC PROTEASE INHIB |
| GCN | 37367 |
| HICL Sequence Number | 041531 |
| HICL Sequence Number Description | DARUNAVIR ETHANOLATE/COBICISTAT |
| Brand/Generic | Brand |
| Proprietary Name | PREZCOBIX |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | DARUNAVIR ETHANOLATE and COBICISTAT |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 150; 800 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | COBICISTAT; DARUNAVIR ETHANOLATE |
| Labeler Name | Janssen Products LP |
| Pharmaceutical Class | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], HIV Protease Inhib |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA205395 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 59676-0575-30 (59676057530)
| NDC Package Code | 59676-575-30 |
|---|---|
| Billing NDC | 59676057530 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE (59676-575-30) |
| Marketing Start Date | 2015-01-31 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 79.5547 |
| Pricing Unit | EA |
| Effective Date | 2024-01-24 |
| NDC Description | PREZCOBIX 800 MG-150 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 2 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |